19/04/2014 21:48:51 Free Membership Login

Corcept Therapeutics News (NASDAQ:CORT)

DateTimeSource
Headline
04/10/20148:21AMPRNUSBrinson Patrick Re-launches Research Department
Brinson Patrick Re-launches Research Department -- Firm Initiates Coverage on Corcept Therapeutics, Ligand Pharmaceuticals, MannKind Corporation, Opexa Therapeutics and Rexahn Pharmaceuticals -- PR Newswire NEW YORK, April 10, 2014 NEW YORK, April 10, 2014 /PRNewswire/ -- Brinson Patrick Securities Corporation  ("Brinson... More...>>
04/02/201412:15PMMWUSUS Oncology Research Joins Corcept Therapeutics' Phase I Breast Cancer Study
US Oncology Research Joins Corcept Therapeutics' Phase I Breast Cancer Study Multi-Center Study Now Enrolling Patients at US Oncology Research Affiliated Sites in Texas and Virginia MENLO PARK, CA and THE WOODLANDS, TX--(Marketwired - Apr 2, 2014) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company... More...>>
03/05/20149:00AMMWUSCorcept Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results
Corcept Therapeutics Announces Fourth Quarter and Full Year 2013 Financial Results MENLO PARK, CA--(Marketwired - Mar 5, 2014) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric... More...>>
01/30/20144:05PMMWUSCorcept Therapeutics Announces Fourth Quarter, Full Year 2013 Revenue and Provides 2014 Outlook
Corcept Therapeutics Announces Fourth Quarter, Full Year 2013 Revenue and Provides 2014 Outlook MENLO PARK, CA--(Marketwired - Jan 30, 2014) - Corcept Therapeutics Incorporated (NASDAQ: CORT) Fourth quarter 2013 revenue up 56% over third quarter 2013 revenue Company anticipates Korlym 2014 revenue to grow to a range of... More...>>
01/27/20148:30AMMWUSCorcept Therapeutics to Announce Fourth Quarter and Full Year Revenue and Corporate Update and Host Conference Call
Corcept Therapeutics to Announce Fourth Quarter and Full Year Revenue and Corporate Update and Host Conference Call MENLO PARK, CA--(Marketwired - Jan 27, 2014) -  Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full year 2013 revenue on January 30, 2014. The Company... More...>>
12/16/20135:05PMZACKSPipeline Progress at Corcept - Analyst Blog
Corcept Therapeutics Inc.'s (CORT) key objective in 2014 is the successful commercialization of its only approved product, Korlym. Corcept launched Korlym in the U.S in Apr 2012. Korlym is approved in the U.S. and the EU as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism... More...>>
12/12/20138:30AMMWUSCorcept Therapeutics Announces Oncology Development Program
Corcept Therapeutics Announces Oncology Development Program Five of Eight Patients With Relapsed, Metastatic Triple-Negative Breast Cancer (TNBC) Experienced a Partial or Complete Response With Mifepristone and Chemotherapy Combination According to Data Presented at the San Antonio Breast Cancer Symposium 2013; Company... More...>>
11/07/20134:38PMMWUSCorcept Therapeutics Announces Third Quarter 2013 Financial Results and Corporate Update
Corcept Therapeutics Announces Third Quarter 2013 Financial Results and Corporate Update MENLO PARK, CA--(Marketwired - Nov 7, 2013) - Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and... More...>>
11/04/20135:00PMMWUSCorcept Therapeutics to Announce Third Quarter 2013 Financial Results and Host Conference Call
Corcept Therapeutics to Announce Third Quarter 2013 Financial Results and Host Conference Call MENLO PARK, CA--(Marketwired - Nov 4, 2013) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter 2013 financial results on November 7, 2013. The Company will host a conference call that... More...>>
08/08/20134:05PMMWUSCorcept Therapeutics Announces Second Quarter 2013 Financial Results and Corporate Update
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its financial results for the quarter ended June 30, 2013. Second Quarter Financial Results Recognized... More...>>
08/01/20134:05PMMWUSCorcept Therapeutics to Announce Second Quarter 2013 Financial Results and Host Conference Call
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter 2013 financial results on August 8, 2013. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, dial 1-888-771-4371 from the United States... More...>>
07/24/20139:00AMMWUSCorcept Therapeutics Announces Partnership With Idis for Global Access to Korlym(R)
Corcept Therapeutics Incorporated (NASDAQ: CORT) announced today that Korlym® (mifepristone) 300 mg Tablets is available to patients outside of the United States through an Idis Access Program. Idis Access Programs enable patients around the world to be prescribed investigational or approved drugs prior to their commercial... More...>>
05/07/20137:40AMZACKSWider-than-Expected Loss at Corcept - Analyst Blog
Corcept Therapeutics Inc. (CORT) posted a loss per share of 11 cents in the first quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago quarter, Corcept reported a loss of 13 cents. Corcept generated revenues of $1.7 million in the first quarter of 2013, missing the Zacks Consensus... More...>>
05/02/20134:05PMMWUSCorcept Therapeutics Announces First Quarter 2013 Financial Results
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its financial results for the quarter ended March 31, 2013. First Quarter Financial Results For... More...>>
04/26/20139:00AMMWUSCorcept Therapeutics to Announce First Quarter 2013 Financial Results and Host Conference Call
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter 2013 financial results on May 2, 2013. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, dial 1-888-771-4371 from the United States... More...>>
03/14/20139:48AMZACKSCorcept's Loss Narrows in 4Q - Analyst Blog
Corcept Therapeutics Inc. (CORT) posted a loss per share of 11 cents in the fourth quarter of 2012 which was narrower than the loss of 12 cents posted in the year-ago quarter Adjusted loss per share was 10 cents (including stock-based compensation but excluding accretion of interest expense related to long-term obligation... More...>>
03/07/20135:01PMMWUSCorcept Therapeutics Announces Fourth Quarter and Full Year 2012 Financial Results
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2012. In April 2012... More...>>
02/15/201312:05PMZACKSCorcept Provides 4Q & 2012 Outlook - Analyst Blog
Corcept Therapeutics Inc. (CORT) recently released preliminary results for the fourth quarter and full year 2012. Corcept expects fourth quarter revenues to come around $1.4 million, up 27.3% from the third quarter. Revenues for 2012 are projected at $3.3 million. Corcept expects to end 2012 with a cash balance of $93.0... More...>>
02/12/20134:05PMMWUSCorcept Therapeutics Announces Fourth Quarter and Full Year Revenue and Corporate Update
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its unaudited net revenue for the quarter and the year ended December 31, 2012 and cash balance... More...>>
01/23/20138:20AMMWUSMerger and Acquisition Activity Expected to Rise in 2013 as Big Pharma Companies Flush With Cash
Lost revenues from expiring patents has played a major part in the Biotech Industry's success in recent years. A total of 676 takeovers of biotechnology and pharmaceutical companies have occurred in the past three years, with an average premium of 38 percent, according to data collected by Bloomberg. Five Star Equities... More...>>


NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq cort140419 21:48